Jyong Biotech Ltd. (MENS)
NASDAQ: MENS · Real-Time Price · USD
2.065
+0.005 (0.24%)
Aug 14, 2026, 11:20 AM EDT - Market open
Jyong Biotech Employees
Jyong Biotech had 27 employees as of December 31, 2025. The number of employees decreased by 4 or -12.90% compared to the previous year.
Employees
27
Change
-4
Growth
-12.90%
Revenue / Employee
n/a
Profits / Employee
-$173,000
Market Cap
153.29M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 27 | - | - |
| Jun 30, 2024 | 31 | - | - |
| Dec 31, 2023 | 31 | -1 | -3.13% |
| Dec 31, 2022 | 32 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Codexis | 146 |
| Molecular Partners AG | 134 |
| Cibus | 118 |
| Nkarta | 108 |
| Armata Pharmaceuticals | 61 |
| OnKure Therapeutics | 45 |
| Aardvark Therapeutics | 40 |
MENS News
- 22 days ago - Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - GlobeNewsWire
- 6 weeks ago - Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - GlobeNewsWire
- 2 months ago - Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - GlobeNewsWire
- 3 months ago - Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - GlobeNewsWire
- 3 months ago - Jyong Biotech Annual report: Q4 2025 - Filings
- 3 months ago - Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio - GlobeNewsWire
- 5 months ago - Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2 - GlobeNewsWire
- 6 months ago - Jyong issues strategic corporate update, completes Phase II trial for MCS-8 - TheFly